Profil
Stephen Bloor is the founder and the Chief Executive Officer of Videregen Ltd., a company founded in 2011.
He also served as the Technical Director of Tissue Science Laboratories Ltd.
from 2000 to 2015.
Aktive Positionen von Stephen Bloor
| Unternehmen | Position | Beginn |
|---|---|---|
Videregen Ltd.
 Videregen Ltd. BiotechnologyHealth Technology Videregen Ltd. operates a regenerative medicine company created to address the chronic shortage of organs for transplantation in the field of tissue decellularisation, regenerative technologies and translation from laboratory to market. Its platform technology uses decellularised organ scaffolds seeded with the patient’s own cells to create non-immunogenic, regenerative bespoke organ replacements. The company was founded by Stephen Bloor in 2011 and is headquartered in Liverpool, The United Kingdom. | Vorstandsvorsitzender | 01.01.2011 |
Ehemalige bekannte Positionen von Stephen Bloor
| Unternehmen | Position | Ende |
|---|---|---|
Tissue Science Laboratories Ltd.
 Tissue Science Laboratories Ltd. Medical SpecialtiesHealth Technology Tissue Science Laboratories Ltd. develops and markets tissue implant products. The company was founded on January 7, 1999 and is headquartered in Watford, the United Kingdom. | Technik-/Wissenschafts-/F&E-Leiter | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Tissue Science Laboratories Ltd.
Tissue Science Laboratories Ltd. Medical SpecialtiesHealth Technology Tissue Science Laboratories Ltd. develops and markets tissue implant products. The company was founded on January 7, 1999 and is headquartered in Watford, the United Kingdom. | Health Technology |
Videregen Ltd.
Videregen Ltd. BiotechnologyHealth Technology Videregen Ltd. operates a regenerative medicine company created to address the chronic shortage of organs for transplantation in the field of tissue decellularisation, regenerative technologies and translation from laboratory to market. Its platform technology uses decellularised organ scaffolds seeded with the patient’s own cells to create non-immunogenic, regenerative bespoke organ replacements. The company was founded by Stephen Bloor in 2011 and is headquartered in Liverpool, The United Kingdom. | Health Technology |
